BiotechTube

LY3849891 + Placebo

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

Trial Timeline

Jun 8, 2022 → May 1, 2026

NCT ID
NCT05395481

About LY3849891 + Placebo

LY3849891 + Placebo is a phase 1 stage product being developed by Eli Lilly for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The current trial status is active. This product is registered under clinical trial identifier NCT05395481. Target conditions include Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD).

What happened to similar drugs?

19 of 20 similar drugs in Metabolic Dysfunction-Associated Steatohepatitis (MASH) were approved

Approved (19) Terminated (4) Active (1)
✅Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
✅Metformin + PlaceboEli LillyApproved
✅Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
✅Rosuvastatin + AtorvastatinAstraZenecaApproved
✅rosuvastatinAstraZenecaApproved
✅Simvastatin + Simvastatin/EzetimibeMerckApproved
✅Simvastatin + Vytorin + Placebo + EzetimibeMerckApproved

Hype Score Breakdown

Clinical
6
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05395481Phase 1Active

Competing Products

20 competing products in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

See all competitors
ProductCompanyStageHype Score
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
35
Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + AmlodipineDaiichi SankyoPhase 3
40
olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomilDaiichi SankyoPhase 3
40
14C-labeled YM178Astellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
LY518674Eli LillyPhase 2
35
Tirzepatide + Retatrutide + PlaceboEli LillyPhase 3
47
Metformin + PlaceboEli LillyApproved
43
Tirzepatide + SemaglutideEli LillyPre-clinical
18
Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
50
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin + AtorvastatinAstraZenecaApproved
43
AZD2693 + PlaceboAstraZenecaPhase 1
29
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
40
rosuvastatinAstraZenecaApproved
43
EfinopegdutideMerckPhase 2
35
MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)MerckPhase 2
27
Vericiguat + PlaceboMerckPhase 2
35
MetforminMerckPhase 2
35